Log In
Print
BCIQ
Print
Print this Print this
 

LGH447

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionOral pan-PIM kinase inhibitor
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat refractory multiple myeloma (MM)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today